Advances in Pharmacology and Pharmacy Vol. 12(4), pp. 367 - 379
DOI: 10.13189/app.2024.120409
Reprint (PDF) (7139Kb)

Albandari Bin-Ammar *
Department of Clinical Nutrition, College of Applied Medical Sciences, University of Ha'il, Saudi Arabia

ABSTRACT

The morbidity of cancer and obesity has been rising at an epidemic rate in recent years. Fatty acid synthase (FAS) is the central enzyme involved in endogenous lipogenesis. It has been postulated that FAS is a viable target for treating cancer and obesity. This study aimed to investigate the FAS inhibitory activity of Euphorbia peplus extract and its secondary metabolites using in vitro and in silico approaches. The inhibitory activity of E. peplus and seven isolated compounds was tested in vitro against chicken FAS due to its similarity to the human enzyme. The results revealed that all compounds as well as the extract inhibited the activity of FAS with compound 2 exhibiting the highest inhibitory activity. The reported IC50 values for the extract were 33.63 ± 0.77 and for 1-7 compounds 38.95 ± 0.98, 19.99 ± 0.35, 22.37 ± 0.62, 27.31 ± 0.95, 24.10 ± 0.47, 22.02 ± 0.63, 66.44 ± 1.59 µg/ml, respectively. In silico work showed the affinity of all compounds toward the thioesterase and KS domains of FAS. All compounds showed hydrogen bonds and hydrophobic interactions with both domains. In conclusion, E. peplus and its secondary metabolites are effective inhibitors of FAS activity and could have beneficial effects against cancer and obesity, pending further investigations.

KEYWORDS
Fatty Acid Synthase, Euphorbia, Medicinal Plants, Cancer, Obesity

Cite This Paper in IEEE or APA Citation Styles
(a). IEEE Format:
[1] Albandari Bin-Ammar , "Fatty Acid Synthase Inhibitory Activity of Euphorbia peplus and its Secondary Metabolites," Advances in Pharmacology and Pharmacy, Vol. 12, No. 4, pp. 367 - 379, 2024. DOI: 10.13189/app.2024.120409.

(b). APA Format:
Albandari Bin-Ammar (2024). Fatty Acid Synthase Inhibitory Activity of Euphorbia peplus and its Secondary Metabolites. Advances in Pharmacology and Pharmacy, 12(4), 367 - 379. DOI: 10.13189/app.2024.120409.